Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Determa_Rx
Determa IO |
| gptkbp:awards |
various industry recognitions
|
| gptkbp:business_model |
B2 B and B2 C
|
| gptkbp:ceo |
Ronald Andrews
|
| gptkbp:clinical_trial |
gptkb:healthcare_organization
various cancer types bladder cancer |
| gptkbp:collaborations |
pharmaceutical companies
|
| gptkbp:community_engagement |
educational outreach
healthcare initiatives patient advocacy programs |
| gptkbp:develops |
liquid biopsy tests
|
| gptkbp:employees |
approximately 50
|
| gptkbp:focus |
cancer diagnostics
|
| gptkbp:founded |
gptkb:2014
|
| gptkbp:future_plans |
strategic partnerships
new product development international expansion increased R& D investment |
| gptkbp:headquarters |
gptkb:Alameda,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Onco Cyte Corporation
|
| gptkbp:invention |
patents
licensing agreements trademarks |
| gptkbp:investment |
gptkb:Europe
gptkb:Asia gptkb:North_America institutional and retail investors |
| gptkbp:mission |
improve cancer patient outcomes
|
| gptkbp:partnership |
gptkb:Johns_Hopkins_University
gptkb:University_of_California gptkb:Cleveland_Clinic various research institutions |
| gptkbp:products |
gptkb:Determa_Rx
Determa Cure Determa IO |
| gptkbp:publishes |
peer-reviewed journals
clinical studies conference presentations |
| gptkbp:receives_funding_from |
gptkb:Company
public offerings |
| gptkbp:regulatory_compliance |
FDA clearance
CLIA certification |
| gptkbp:research_focus |
early cancer detection
|
| gptkbp:revenue |
$10 million (2020)
|
| gptkbp:strategic_importance |
increase market share
develop new technologies improve patient access enhance research capabilities expand product line |
| gptkbp:symbol |
OCX
|
| gptkbp:technology |
genomic profiling
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.oncocyte.com
|
| gptkbp:bfsParent |
gptkb:Lab_Corp
|
| gptkbp:bfsLayer |
4
|